Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine
Comparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.
Rhode Island Hospital
120 participants
Jan 20, 2026
INTERVENTIONAL
Conditions
Summary
The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.
Eligibility
Inclusion Criteria3
- Patients undergoing elective total hip arthroplasty
- years old
- ASA 1-3 classifications
Exclusion Criteria13
- ASA classification of 4 or greater
- Infection at the site of nerve blockade
- Coagulopathy
- Known allergy to study medications
- Chronic opioid consumption (\>3 months)
- Currently using lidocaine patches
- Pre-existing neuropathy
- A history of CVA
- High grade atrioventricular block (cardiac conduction system impairment)
- Organ dysfunction (cardiac failure, respiratory failure, end stage renal disease, hepatic dysfunction, hypoalbuminemia)
- Morbid obesity (≥40 kg/m2)
- Prior surgery in supra and/or infrainguinal region
- Non-English-speaking participants
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants in the experimental arm receive a preoperative suprainguinal fascia iliaca block consisting of 30 mL of 0.25% ropivacaine combined with perineural dexmedetomidine at a dose of 1 mcg/kg.
In the experimental arm, ropivacaine (30 mL of 0.25%) is administered with dexmedetomidine. In the active comparator arm, ropivacaine (30 mL of 0.25%) is administered alone without any dexmedetomidine medication.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07316166